Role of polypeptides in the treatment and diagnosis of osteoporosis

Peptides

Volumn 20, Issue 4, 1999, Pages 523-537

  Kundu, Bijoy ^a   Khare, Sanjay K ^a   Singh, Geeta ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Bone mineral density; Bone remodeling and coupling; Calcitonins; Growth factors; Neuropeptides; Polypeptides

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CALCIUM; COLLAGEN; ECHISTATIN; FLUORIDE; GROWTH FACTOR; GROWTH HORMONE; INTERFERON; INTERLEUKIN 1; LYMPHOKINE; NEUROPEPTIDE; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE RELATED PROTEIN; SOMATOMEDIN; SUBSTANCE P; TRANSFORMING GROWTH FACTOR; VITAMIN D;

BONE METABOLISM; BONE REMODELING; HORMONE SUBSTITUTION; HUMAN; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

AGED; AMINO ACID SEQUENCE; BONE REMODELING; CALCITONIN; FEMALE; GROWTH SUBSTANCES; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEUROPEPTIDES; OSTEOPOROSIS; PEPTIDES;

EID: 0032886952     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00034-0     Document Type: Review

References (165)

1. Adachi J.D., Bensen W.G., Bell M.J., Bianchi F.A., Cividino A.A., Craig G.L., Sturtridge W.C., Sebaldt R.J., Steele M., Gordon M., Themeles E., Tugwell P., Roberts R., Gent M. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol. 36:1997;255-259.
2. Adachi M. The correlation of bone mineral density and biochemical fracture risk. Calcif Tissue Int. 59:1996;S16-S19.
3. Bab I. Regulatory role of osteogenic growth peptide in proliferation, osteogenesis and hemopoiesis. Clin Orthop. 313:1995;64-68.
4. Bab I., Gazit D., Chorev M., Muhlard A., Shteyer A., Greenberg Z., Namdar M., Kahn A.J. Histone H4-related osteogenic growth peptide (OGP) a novel circulating stimulator of osteoblastic activity . EMBO J. 11:1992;1867-1873.
5. Basharat Rihani S., Lewinson D. PTHrP (107-111) inhibits in vivo reabsorption that was stimulated by PTHrP (1-34) when applied intermittently to neonatal mice. Calcif Tissue Int. 61:1997;426-428.
6. Beaudreuil J., Mbalaviele G., Cohn-Sohal M., Morieux C., De Vernejoul M.C., Orcel P. Short term local injections of TGF-β1 decrease ovariectomy-stimulated osteoclastic reabsorption in vivo in rats. J Bone Miner Res. 10:1995;971-977.
7. Bevis P.J., Zaidi M., MacIntyre I. A dual effect of calcitonin gene related peptide on plasma calcium levels in the chick. Biochem Biophys Res Commun. 169:1990;846-850.
8. Bjurhalm A., Kreicbergs A., Brodin E., Schultzberg M. Substance P, and CGRP-immunoreactive nerves in bone. Peptides. 9:1988;165-171.
9. Bonde M.M., Garnero P., Fledelius C., Qvist P., Delmas P.D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 12:1997;1028-1034.
10. Boonen S., Broos P., Dequeker J., Bouillon R. The prevention or treatment of age related osteoporosis in the elderly by systemic recombinant growth factor therapy (rhIGF-I or rhTGF β) a perspective . J Intern Med. 242:1997;285-290.
11. Bowers C.Y., Mommamy F.A., Reynolds G.A., Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 114:1984;1537-1541.
12. Byers P.H., Steiner R.D. Osteogenesis imperfecta. Annu Rev Med. 43:1992;269-282.
13. Canalis E. Insulin like growth factors and their role in osteoporosis. Calcif Tissue Int. 58:1996;133-134.
14. Care A.D., Abbas S.K., Pickard D.W., Barri M., Drinkhill M., Findlay J.B.C., White I.R., Caple I.W. Stimulation of ovine placenta transport of calcium and magnesium by mid-molecule fragments of human parathyroid hormone-related protein. Q J Exp Physiol. 75:1990;605-608.
15. Celeste A.J., Iannazzi J.A., Taylor R.C., Rodney M., Hewick R.M., Vicki R., Wang E.A., Wozney J.M. Identification of transforming growth factor beta family members present in bone-inductive proteins purified from bovine bone. Proc Natl Acad Sci USA. 87:1990;9843-9847.
16. Christiansen C., Riis B.J., Nilas L., Rodbro P., Deffos L. Uncoupling of bone formation and reabsorption by combined estrogens and progestrogen therapy in postmenopausal osteoporosis. Lancet. 2:1985;800-801.
17. Chyun Y.S., Kream B.E., Raisy L.G. Cortisol decreases bone formation by inhibiting periosteal cell proliferation. Endocrinology. 114:1984;477-480.
18. Compston J.E. Prevention and management of osteoporosis. Drugs. 53:1997;727-735.
19. Consensus development conference diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
20. Cook S.D., Baffes G.C., Wolfe M.W., Sampath T.K., Rueger D.C. Recombinant hBMP-7 induces healing in canine long bone segmental defect model. Clin Orthop. 301:1994;302-312.
21. Copp D.H., Cameron E.C., Cheney B.A., Davidson A.G.F., Henze K.G. Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology. 70:1962;683-689.
22. Cornish J., Callon K.E., Cooper G.J., Reid I.R. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun. 207:1995;133-139.
23. Cornish J., Callon K.E., Nicholson G.C., Reid I.R. Parathyroid hormone related protein (107-139) inhibits bone reabsorption in vivo. Endocrinology. 138:1997;1299-1304.
24. Cornish J., Callon K.E., Reid I.R. An in vivo model of the rapid assessment of the local effects of parathyroid hormone on bone histomorphometry. Bone. 17:1995;S249-S254.
25. Cummings S.R., Black D.M., Nevitt M.C. Bone density at various sites for prediction of hip fractures. The study of osteoporotic fracture research group. Lancet. 341:1993;72-75.
26. Cummings S.R., Kelsey J.C., Neviti M.C., O'Dowd K.J. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 7:1985;178-208.
27. Delany A.M., Pash J., Canalis E. Cellular and clinical perspectives on skeletal insulin like growth factor I. J Cell Biochem. 55:1994;328-333.
28. Eastell R. Treatment of postmenopausal women. N Engl J Med. 338:1998;736-745.
29. Ejersted C., Andreassen T.T., Nilsson M.H.L., Oxlund H. Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats. Eur J Endocrinol. 130:1994;201-207.
30. Ejersted C., Andreassen T.T., Oxlund H., Jorgensen P.H., Bak B., Haggblad J., Torring O., Nilsson M.H. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res. 8:1993;1097-1101.
31. Ellerington M.C., Hillard T.C., Whitcroft S.I.J., Marsh M.S., Lees B., Banks L.M., Whitehead M.I., Stevenson J.C. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int. 59:1996;6-11.
32. Elma K. Osteoinductive proteins. Ann Med. 25:1993;395-402.
33. Engelman V.W., Nickols G.A., Ross F.P., Horton M.A., Griggs D.W., Settle S.L., Ruminski P.G., Teitelbaum S.L. A peptidomimetic antagonist of the α(v)β3 integrin inhibits bone reabsorption in vitro and prevents osteoporosis in vivo. J Clin Invest. 99:1997;2284-2292.
34. Erlebacher A., Derynck R. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis like phenotype. J Cell Biol. 132:1996;195-210.
35. Fenton A.J., Kemp B.E., Hammonds R.G., Mitchelhill K., Moseley J.M., Martin T.J., Nicholson G.C. A potent inhibitor of osteoclastic bone reabsorption within a highly conserved pentapeptide region of parathyroid hormone related protein. PTHrP (107-111). Endocrinology. 129:1991;3424-3426.
36. Fenton A.J., Kemp B.E., Neil Kent G.N., Moseley J.M., Zhang M.H., Rowe D.J., Britto J.M., Martin T.J., Nicholson G.C. A carboxyl-terminal peptide from the parathyroid hormone related protein inhibits bone reabsorption by osteoclasts. Endocrinology. 129:1991;1762-1767.
37. Finkelman R.D., Bell N.H., Strong D.D., Demers L.M., Baylink D.J. Ovariectomy selectively reduces the concentration of TGF-β in rat bone implications for estrogen deficiency-associated bone loss . Proc Natl Acad Sci USA. 89:1992;12190-12193.
38. Finkelman R.D., Easo A.L., Rakijian D.R., Tutundzhyan Y., Hardesty R.A. Elevated IGF-II and TGFβ concentrations in human calvarial bone potential mechanism for increased graft suvival and resistance to osteoporosis . Plastic Reconstr Surg. 93:1994;732-738.
39. Fisher J.E., Caulfield M.P., Sato M., Quartuccio H.A., Gould R.J., Garsky V.M., Rodan G.A., Rosenblatt M. Inhibition of osteoclastic bone reabsorption in vivo by echistatin, an RGD containing protein. Endocrinology. 132:1993;1411-1413.
40. Fleischer D., Niemeic S.M., Oh C.K., Hu Z., Ramachandran C., Weiner N. Topical delivery of growth hormone releasing peptide using liposomal system as in vitro study using hairless mouse skin. Life Sci. 57:1995;1293-1297.
41. Forero M.S., Klein R.F., Nissenson R.A., Nelson K., Heath H. III, Arnard C.D., Riggs B.L. Effect of age on circulating immunoreactive and bioactive parathyroid hormone levels in women. J Bone Miner Res. 2:1987;363-366.
42. Foresta C., Zanatte G.P., Busnardo B., Scanelli G., Scandellari C. Testosterone and calcitonin plasma levels in hypogonadal osteoporotic young men. J Endocrinol Invest. 8:1985;377-379.
43. Foster G.V., Baghdianz A., Kumar M.A., Slack E., Soliman H.A., MacIntyre I. Thyroid origin of calcitonin. Nature. 202:1964;1303-1305.
44. Galante L., Joplin G.F., MacIntyre I., Woodhouse N.J.Y. The calcium lowering effect of synthetic human, porcine, and salmon calcitonin in patients with Pagets disease. Clin Sci Mol Med. 44:1976;605-610.
45. Gallaghar J.C., Jerpbak C.M., Jee W.S.S., Johnson K.A., Deluca H.F., Riggs B.L. 1,25 dihydroxy vitamin D3 short and long term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis . Proc Natl Acad Sci USA. 79:1982;3325-3329.
46. Ganero P., Delmas P.D. New developments in biochemical markers for osteoporosis. Calcif Tissue Int. 59:1996;S2-S9.
47. Gennari C., Chierichetti S.M., Vibelli C., Francini G., Maioli E., Gonnelli S. Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man. Curr Ther Res. 30:1981;1024-1032.
48. Gennari C., Gonnelli S., Agnusdei D., Civitelli R. Biological activity of different calcitonins in men. Exp Gerontol. 25:1990;339-347.
49. Gertz B.J., Shao P., Hanson D.A., Quan H., Harris S.T., Genant H.K., Chesnut C.H. III, Eyre D.R. Monitoring bone reabsorption in early postmenopausal women by an immunoassay for cross linked collagen peptides in urine. J Bone Miner Res. 9:1994;135-142.
50. Gonnelli S., Cepollaro C., Montomoli M., Gennari L., Montagnani A., Palmieri R., Gennari C. Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin a placebo controlled study . Clin Endocrinol. 46:1997;55-61.
51. Goodman W.G., Hori M.T. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes. 33:1984;825-831.
52. Greenberg Z., Gavish H., Muhirad A., Chorev M., Shteyer A., Namdar M., Tartakovsky A., Bab I. Isolation of osteogenic growth peptide from osteoblastic MC3T3 E1 cell cultures and demonstration of osteogenic growth peptide binding proteins. J Cell Biochem. 65:1997;359-367.
53. Gueguen R., Jouanny P., Guillemin F. Segregation analysis and variants components analysis of bone mineral density in health families. J Bone Miner Res. 12:1995;2017-2022.
54. Gunness-Hey M., Hock J.M. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Relat Res. 5:1984;177-181.
55. Hakala J.M., Valo T., Vihanainen S., Hermmen J., Heino P., Halme M., Koskinene A.M. Constrained analogues of the CGRP. Biochem Biophy Res Commun. 202:1994;497-503.
56. Hakala J.M., Vihinen M. Modelling the structure of calcitonin gene related peptide. Protein Engin. 7:1994;1069-1075.
57. Heany R.P. The bone remodeling transient implications for the interpretation of clinical studies of bone mass change . J Bone Miner Res. 9:1994;1515-1523.
58. Hickman J., McElduff A. Insulin promotes growth of the cultured rat osteosarcome cell line UMR-106-01 an osteoblast like cell . Endocrinology. 124:1989;701-706.
59. Hiraki Y., Inoue H., Shigeno C., Sanma Y., Bentz H., Rosen D.M., Asada A., Suzuki F. Bone morphogenic proteins promote growth and expression of the differentiated phenotype of rabbit chondrocytes and osteoblastic MC 3T3-E1 cells in vitro. J Bone Miner Res. 6:1991;1373-1385.
60. Holloway L., Kohlmeier l, Kent K., Marcur R. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab. 82:1997;1111-1117.
61. Hough S., Avioli L.V., Bergfeld M.A., Fallon M.D., Slatopolsky E., Teitslbaum S.L. Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology. 108:1981;2228-2234.
62. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β Nature Med. 2:1996;1132-1136.
63. Hurley D.L., Tiegs R.D., Wahner H.W., Heath H. III. Axial and appendicular bone mineral density in patients with long term deficiency or excess of calcitonin. N Engl J Med. 317:1987;537-541.
64. Hynes R.O. Integrins versatility, modulation, and signaling in cell adhesion . Cell. 69:1992;11-25.
65. Ilson B.E., Jorkasky D.K., Curnow R.T., Stote R.M. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endo Metab. 69:1989;212-214.
66. Iwasaki M., Nakahara H., Nakase T., Kimura T., Takaoka K., Caplan A.I., Ono K. Bone morphogenetic protein 2 stimulates osteogenesis but does not affect chondrogenesis in osteochondrogenic differentiation of periosteum-derived cells. J Bone Miner Res. 9:1994;1195-1204.
67. Jonsson K.B., Wiberg K., Ljunghall S., Ljunggren O. Insulin like growth factor I does not stimulate bone reabsorption in cultured neonatal mouse calvarial bones. Calcif Tissue Int. 59:1996;366-370.
68. Kalu D.N., Salerno E., Higami Y., Liu C.C., Ferraro F., Salih M.A., Arjmandi B.H. In vivo effects of TGF-β2 in ovariectomized rats. Bone Miner. 22:1993;209-220.
69. Kanis J.A., Melton L.J. III, Christiansen C. The diagnosis of osteoporosis. J Bone Miner Res. 9:1994;1137-1141.
70. Kapetanos G., Symeonides P.P., Dimitriou C., Karakatsanis K., Potoupnis M. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis. Acta Orthop Scand. 275:(Suppl.):1997;108-111.
71. Kasperk C.H., B'rcsok I., Schairer H.U., Schneider U., Nawroth P.P., Niethard F.U., Ziegler R. Endothelin 1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int. 60:1997;368-374.
72. Kassem M., Brixen K., Blum W.F., Moseklide L., Eriksen E.F. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. J Bone Miner Res. 9:1994;1365-1370.
73. Kawakami T., Uji H., Antoh M., Hasegawa H., Kise T., Eda S. Squalane as a possible carrier of BMP. Biomaterials. 14:1993;575-577.
74. Kessenich C.R. Update on pharmacological therapies for osteoporosis. Nurse Pract. 21:1996;19-24.
75. Kimble R.B., Vannice J.L., Bloedow D.C. Interleukin 1 receptor antagonist decreases bone loss and bone reabsorption in ovariectomized rats. J Clin Invest. 93:1994;1959-1967.
76. Klibanski A., Greenspan S.L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 315:1986;542-546.
77. Kream B.E., Smith M.D., Canalis E., Raisz L.G. Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology. 116:1985;296-302.
78. Lind M., Overgaard S., Soballe K., Nguyen T., Ongpipattanakul B., Bunger C. TGF-β1 enhances bone healing to unloaded tricalcium phosphate coated implants an experimental study in dogs . J Orthop Res. 14:1996;343-350.
79. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med. 103:1997;3S-11S.
80. Lips P., Obrant K.J. Pathogenesis and treatment of hip fractures. Osteoporosis Int. 1:1991;218-231.
81. Locklin R.M., Williamson M.C., Beresford J.N., Triffit J.T., Owen M.E. In vitro effects of growth factors and dexamethasone on rat marrow stromal cells. Clin Orthop. 313:1995;27-35.
82. Malluchi H.H., Fangere M.C., Rush M., Friesler R. Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function in experimental beagle dogs. Endocrinology. 119:1986;2649-2654.
83. Mangin M., Webb A.C., Dreyer B.E., Posillico J.T., Ikeda K., Weir E.C., Stewart A.F., Bander N.H., Milstone L., Barton D.E., Francke U., Broadus A.E. Identification of a cDNA encoding a parathyroid hormone like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA. 85:1988;597-601.
84. Marie P. Growth factors and bone formation in osteoporosis role for IGF-I and TGF-β Rev Rhum Engl Ed. 64:1997;44-53.
85. Mayahara H., Ito T., Nagai H., Miyajima H., Tsukuda S., Mizoguchi J., Kato K. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors. 9:1993;73-80.
86. McQueney M.S., Amegadzie B.Y., D'Alessio K.D., Hanning C.R., McLaughlin M.M., McNutty D., Carr S.A., Ijames C., Kurdyla J., Jones C.S. Autocatalytic activation of human cathepsin K. J Biol Chem. 272:1997;13955-13960.
87. Melton L.J. Epidemiology of hip fractures implications of the exponential increase with age . Bone. 18:1996;1215-1218.
88. Melton LJ III, Riggs BL. The Osteoporotic Syndrome. Avioli LV, Ed. New York: Grune and Stratton, 1994:45-72.
89. Melton L.J. III, Waner H.W., Richelson L.S., O'Fallon W.M., Riggs B.L. Osteoporosis and the risk of hip fracture. Am J Epidemiol. 124:1986;254-261.
90. Miyamoto S., Takaoka K., Okada T., Yashikawa H., Hashimoto J., Suzuki S., Ono K. Polylactic acid-polyethylene glycol block copolymer. A new biodegradable synthetic carrier for bone morphogenetic protein. Clin Orthop. 294:1993;333-343.
91. Moseklide L., Danielson C.C., Soggard C.H., McOsker J.E., Wronksi T.J. The anabolic effects of parathyroid hormone on cortical bone mass dimensions and strength assessed in a sexually mature, ovariectomized rat model. Bone. 16:1995;223-230.
92. Mundy G.R. Growth factors as potential therapeutic agents in osteoporosis. Instr Course Lect. 46:1997;495-498.
93. Mundy G.R. Is prolonged stimulation of bone growth a therapeutic possibility? Mol Cell Endocrinol. 75:1991;C19-C25.
94. Owan I., Ibaraki K. The role of calcitonin gene-related peptide (CGRP) in macrophages the presence of functional receptors and effects on proliferation and differentiation into osteoclast-like cells . Bone Miner. 24:1994;151-164.
95. Ozakaynak E., Schnegelsberg P.N.J., Jin D.F., Clifford G.M., Warren F.D., Eric A., Oppermann H. Osteogenic protein 2. J Biol Chem. 267:1992;25220-25227.
96. Parfitt A.M. Morphologic basis of bone mineral measurements transient and steady state effects of treatment in osteoporosis . Miner Electrolyte Metab. 4:1980;273-287.
97. Postlethwaite A.E., Raghow R., Stricklin G., Ballaou L., Sampath T.K. Osteogenic protein 1, a bone morphogenetic member of the TGFβ super family, showed chemotactic but not fibrogenic properties with TGF beta. J Cell Physiol. 161:1994;562-570.
98. Pumarino H., Pumarino M.G. Cytokines, growth factors and metabolic bone diseases. Rev Med Chil. 124:1996;248-257.
99. Pun K.K., Lau P., Ho P.W. The characterization, regulation and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res. 4:1989;853-862.
100. Raisz L.G. Effect of corticosteroid on calcium metabolism. Prog Biochem Pharmacol. 17:1980;212-219.
101. Raisz L.G. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med. 318:1988;818-828.
102. Ray N.F., Chan C.K., Thamer M., Meton C.J. III. Medical expenditure for the treatment of osteoporotic fractures in the United States in 1995. J Bone Miner Res. 12:1997;24-35.
103. Reeve J., Arlot M.E., Bradbeer J.N. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporosis Int. 3:1993;199-203.
104. Reid I.R., Evans M.C., Cooper G.J.S., Ames R.W., Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 265:1993;E655-E659.
105. Ribot C.A., Tremolliries F.A. Effect of estrogens on bone and other systems and hormonal substitute treatment. Curr Opin Rheumatol. 9:1997;362-369.
106. Riggs B.L., Melton L.J. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med. 75:1983;899-901.
107. Riggs B.L., Melton L.J. III. Involutional osteoporosis. N Engl J Med. 314:1986;1676-1686.
108. Riggs B.L., Wahner H.W., Melton L.J. III, Richelson L.S., Judd H.L., Offord K.P. Rates of bone loss in the appendicular and axial skeletons of women. J Clin Invest. 77:1986;1487-1491.
109. Rixon R.H., Whitefield J.F., Gagnon L., Issacs R.J., Maclean S., Chakravarty B., Durkin J.P., Neugebauer W., Ross V., Sung W., Willick G.E. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylylcyclase. J Bone Miner Res. 9:1994;1179-1189.
110. Robbins S.L., Coltran R.S. Pathologic basis of diseases. 1979;W.B. Sunders Co.
111. Rodda C.P., Kubota M., Heath J.A., Ebeling P.R., Moseley J.M., Care A.D., Caple I.N., Martin T.J. Evidence for a novel parathyroid hormone related protein in fetal lamb parathyroid glands and sheep placenta comparisons with a similar protein implicated in humoral hypercalcemia of malignancy . J Endocrinol. 117:1988;261-271.
112. Rubin C.D. Age related osteoporosis. Am J Med Sci. 301:1991;281-298.
113. 2D3. Calcif Tissue Int. 59:1996;291-296.
114. Ruoslahti E., Pierschbacher M.D. New perspective in cell adhesion RGD and integrins . Science. 238:1987;491-497.
115. Ruoslathi E. Integrins. J Clin Invest. 87:1991;1-5.
116. Rutherford R.B., Wahle J., Tucker M., Rueger D., Charaette M. Induction of reparative dentine formation in monkeys by recombinant human osteogenic protein 1. Arch Oral Biol. 38:1993;571-576.
117. Saggese G., Baroncilli G.I., Bertelloni S., Cinquanta L., Di Nero G. Effects of long term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr. 122:1993;37-45.
118. Sampath T.K., Maliakal J.C., Hanschka P.V., Jones W.K., Sasak H., Tucker R.F., White K.H., Coughlin J.E., Tucker M.M., Pang R.H. Recombinant human osteogenic protein 1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem. 267:1992;20352-20362.
119. Sandhu H.S., Herskovits M.S., Singh I.J. Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec. 219:1987;32-38.
120. Sasno Y., Ohtani E., Narika K., Kagayama M., Murata M., Satito T., Shigenobu K., Takita H., Mizuno M., Kuboki Y. BMPs induce direct bone formation in ectopic sites independent of the endochondral ossification in vivo. Anal Rec. 236:1993;373-380.
121. Sato M., Garsky V., Majeska R.J. Structure activity studies of the echistatin inhibition of bone reabsorption. J Bone Miner Res. 9:1994;1441-1449.
122. Sato M., Sardana M.K., Grasser W.A., Garsky V.N.M., Murray J.M., Gould R.J. Echistatin is a potent inhibitor of bone reabsorption in culture. J Cell Biochem. 111:1990;1713-1723.
123. Sebley P.L., Peacock M., Baikworth S.A., Brown W.B., Taylor G.A. Early effects of ethinyloestradiol and norethisterone treatment in postmenopausal women on bone reabsorption and calcium regulating hormone. Clin Sci. 69:1985;265-271.
124. Seeman E., Hopper J.L., Bach L.A., Cooper M.E., Parkinson E., McKay J., Jerums G. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 320:1989;554-558.
125. Seeman E. Osteoporosis trials and tribulations . Am J Med. 103:1997;74S-89S.
126. Sherman M.S. The nerves of bone. J Bone Joint Surg. 45-A:1963;522-528.
127. Shih C., Bernard G.W. Neurogenic substance P stimulates osteogenesis in vitro. Peptides. 18:1997;323-326.
128. Silverman S.L. Nasal calcitonin. Endocrine. 6:1997;199-202.
129. Simon LS, Krane SMK. Procollagen extension peptides as markers of collagen synthesis. In: Frame B, Potts JT Jr, Eds., Clinical disorders of bone and mineral metabolism. Netherlands: Excerpta Medica, Amsterdam, pp. 108-11.
130. Soroko S.B., Barrett-Connor E., Edelstein S.L. Family history of osteoporosis and bone mineral density at the axial skeleton the Rancho Bernardo study . J Bone Mineral Res. 9:1994;761-769.
131. Stanley H.L., Schmitt B.P., Poses R.M., Diess W.P. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc. 39:1991;766-771.
132. Suva L.J., Winslow G.A., Wettenhall R.E.H., Hammonds R.G., Moseley J.M., Diefenbach-Jagger H., Rodda C.P., Kemp B.E., Rodriguez H., Chen E.Y., Hudson P.J., Martin T.J., Wood W.I. A parathyroid hormone-related protein implicated in malignant hypercalcemia cloning and expression . Science. 237:1987;893-896.
133. Tamura T., Miyaura C., Owan I., Suda T. Mechanism of action of amylin in bone. J Bone Physiol. 153:1992;6-14.
134. Teigs R.D., Body J.J., Wahner H.W., Barta J., Riggs B.L., Heath H. III. Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med. 312:1985;11097-11100.
135. Thiede M.A., Strewler G.J., Nissenson R.A., Rosenblatt M., Rodan G.A. Human renal carcinoma expresses two messages encoding a PTH like peptide evidence for alternative splicing of a single copy gene . Proc Natl Acad Sci USA. 85:1988;4605-4609.
136. Thompson S.K., Halbert S.M., Bossard M.J., Tomaszek T.A., Levy M.A., Zhao B., Smith W.W., Abdel-Meguid S.S., Janson C.A., D'Alessio K.J., McQueney M.S., Amegadzie B.Y., Hanning C.R., Desjarlias R.L., Briand J., Sarkar S.K., Huddleston M.J., Ijames C.F., Carr S.A., Garnes K.T., Shu A., Heys J.R., Bradbeer J., Zembryki D., Lee-Rykaczewski L., James I.E., Lark M.W., Drake F.H., Gowen M., Gleason J.G., Vener D.F. Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci USA. 94:1997;14249-14254.
137. Togari A., Arai M., Mizutani S., Koshihara Y., Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett. 233:1997;125-128.
138. Uitterlinden A.G., Burger H., Huang Q., Yue F., McGuigan F.E.A., Grant S.F.A., Hofman A., VanLeeuwen J.P.T.M., Pols H.A.P., Ralston S.H. Relation of alleles of the collagen type Ia1 gene to bone density and the risk of osteoporotic fractures in post menopausal women. N Engl J Med. 338:1998;1016-1020.
139. Umpierrez G.E., Zlatev T., Spanheimer R.G. Correlation of altered collagen metabolism in diabetic animals with insulin therapy. Matrix. 9:1989;336-342.
140. Valentijn K., Gutow A.P., Troiano N., Gundberg C., Gilligan J.P., Vignery A. Effects of calcitonin gene related peptide in bone turnover in ovariectomized rats. Bone. 21:1997;269-274.
141. Van der Pluijm G., Mouthaan H., Baas C., de Groot H., Papapoulos S., Lowik C. Integrins and osteoclastic reabsorption in three bone organ cultures differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation . J Bone Miner Res. 9:1994;1021-1028.
142. Verhaeghe J., Suiker A.M.H., Nyomba B.L., Visser W.J., Einhorn T.A., Dequeker E.J., Bouillon R. Bone mineral homeostasis in spontaneously diabetic rats. II. Impaired bone turnover and decreased osteocalcin synthesis. Endocrinology. 124:1989;573-582.
143. Vickery B.H., Avnur Z., Cheng Y. RS 66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized osteopenic rats. J Bone Miner Res. 11:1996;1943-1951.
144. Wang E.A., Rosen V., D'Alessandro J.S., Bauduy M., Cordes P., Harada T., Israel D.I. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA. 87:1990;2220-2224.
145. Wettenhall R.E.H., Schwartz P.L., Bornstein J. Actions of insulin and growth hormone on collagen and chondroitin sulfate synthesis in bone organ culture. Diabetes. 18:1969;280-284.
146. 2 (Ostabolin). Calcif Tissue Int. 58:1996;81-87.
147. 2 to stimulate femoral trabecular bone growth in ovariectomised rats. Calcif Tissue Int. 61:1997;322-326.
148. 2 to stimulate femoral trabecular bone growth in ovariectomised rats. Calcif Tissue Int. 60:1997;26-29.
149. Who are candidates for prevention and treatment for osteopenia? Osteoporosis Int 1997;7:1-6.
150. Wilson R., Rao S.D., Kleerekoper M., Parfitt A.M. Incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res. 2:1987;S19.
151. Wimalawansa S.J., Gunasekra R.D., Datta H.K. Hypocalcemic actions of amylin amide in humans. J Bone Miner Res. 7:1992;1113-1116.
152. Woo J.T., Yamaguchi K., Hayama T. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone reabsorption in vitro and in vivo. Eur J Pharmacol. 300:1996;131-135.
153. Wozney J.M., Rosen V., Celste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewich R.M., Wang E.A. Novel regulators of bone formation molecular clones and activities . Science. 242:1988;1528-1534.
154. Wright N.M., Papadea N., Wentz B., Hollis B., Willi S., Bell N.H. Increased serum 1,25-dihydroxyvitamin D after growth hormone administration is not parathyroid hormone-related. Calcif Tissue Int. 61:1997;101-103.
155. Wright N.M., Renault J., Hollis B., Bell N.H., Key L.L. Effect of growth hormone on bone bone mineral density, trabecular bone volume, and alkaline phosphatase improve or are restored in the dwarf rat treated with growth hormone . J Bone Miner Res. 10:1995;127-131.
156. Yamaguchi M. Beta-alanyl-L-histidinato zinc and bone reabsorption. Gen Pharmacol. 26:1995;1179-1183.
157. Yamaguchi M., Ehara Y. Effect of essential trace metal on bone metabolism in the femoral-metaphyseal tissues of rats with skeletal unloading comparison with zinc-chelating dipeptide . Calcif Tissue Int. 59:1996;27-32.
158. Yamaguchi M., Kishi S. Differential effects of insulin and insulin like growth factor-I in the femoral tissues of rats with skeletal unloading. Calcif Tissue Int. 55:1994;363-367.
159. Yamaguchi M., Oishi H., Suketa Y. Stimulatory effect of zinc on bone formation in tissue culture. Biochem Pharmacol. 36:1987;4007-4012.
160. Yamaguchi M., Sakurai T., Ohtaki J., Hoshi T. Simulated weightlessness and bone metabolism evidence for direct gravitational effect and its related insulin action . Res Exp Med. 191:1991;273-280.
161. Yamaguchi M., Yamaguchi R. Action of zinc on bone metabolism in rats increases in alkaline phosphatase activity and DNA content . Biochem Pharmacol. 35:1986;773-777.
162. Young G., Marcus R., Minkoff J.R., Kim L.Y., Segre G.V. Age related rise in parathyroid hormone in man the use of intact and midmolecule antisera to distinguish hormone secretion from retention . J Bone Miner Res. 2:1987;367-374.
163. Zaidi M., Brain S.D., Tippins J.R., DiMarzo V., Moonga B.S., Chambers T.J., Morris H.R., MacIntyre I. Structure activity relationship of human calcitonin gene related peptide. Biochem J. 269:1990;775-780.
164. Zamboni G., Antoniazzi F., Radetti G., Musumeci C., Tato L. Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency. J Pediatr. 119:1991;483-548.
165. Zhang W.Z., Yu S.F., Zheng L.F. Effect of calcitonin gene related peptide on bone reabsorption mediated by IL-1. Clin Med J. 107:1994;351-354.